Selective serotonin reuptake inhibitors: Relevance of differences in their pharmacological and clinical profiles

CNS Drugs

Volumn 7, Issue 6, 1997, Pages 452-467

  De Jonghe, Frans ^a,c   Swinkels, Jan ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CLINICAL PRACTICE; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030790659     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199707060-00004     Document Type: Review

References (47)

1. Kasper S, Lépine JP, Mendlewicz J, et al. Efficacy, safety and indications for tricyclic and the newer antidepressants. Depression 1995; 2: 127-37
2. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression; a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994; 8: 238-49
3. Montgomery SA, Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol 1995; 9 Suppl. 4: 33-40
4. Henry JA. Toxicity antidepressants. Int Clin Psychopharmacol 1992; 6 Suppl. 6: 22-7
5. Hyttel J. Comparative pharmacology of selective serotonin re-uptake inhibitors (SSRIs). Nord J Psychiatry 1993; 47 Suppl. 30: 5-12
6. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993; 24: 203-20
7. Lane R, Baldwin D, Preskorn S. The SSRIs: advantages, disadvantages and differences. J Psychopharmacol 1995; 9 Suppl. 2: 163-78
8. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994; 9 Suppl. 1: 19-26
9. Leonard BE. SSRI differentiation: pharmacology and pharmacokinetics. Hum Psychopharmacol 1995; 10 Suppl. 3: S149-58
10. Ciraulo DA, Shader RI, Greenblatt DJ. SSRI drug-drug interactions. In: Ciraulo DA, Shader RI, Greenblatt DJ, et al., editors. Drug interactions in psychiatry. Baltimore (MD): Williams & Wilkins, 1995; 64-6
11. Coupland NJ, Bells CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996; 16: 356-62
12. Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 1993; 54 (9 Suppl.): 14-34
13. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993; 24: 203-20
14. Riesenman C. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 1995; 15 Suppl.: 84s-99s
15. Shader RI, von Moltke LL, Schmider J, et al. The clinician and drug interactions - an update. J Clin Psychopharmacol 1996; 16: 197-200
16. Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995; 6: 287-95
17. Nemeroff CB, DeVane CL, Pollock BC. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153: 311-20
18. Gagiano CA. A double blind comparison of paroxetine and fluoxetine in patients with major depression. Br J Clin Res 1993; 4: 145-52
19. Tignol J. A double-blind, randomized, fluoxetine-controlled. multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 1993; 13 Suppl. 2: 18S-22S
20. de Wilde J, Spiers R, Mertens C, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993; 83: 141-5
21. Schöne W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993; 13: 34-9
22. Ontiveros A, Garcia-Barriga C. A double-blind study with paroxetine vs fluoxetine in depressive patients [abstract]. Biol Psychiatry 1994; 35: 667
23. Aguglia E, Casacchia M, Cassano GB, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993; 8: 197-202
24. Newhouse PA, Richter EM. SSRIs in depressed elderly: a double-blind comparison of sertraline and fluoxetine in depressed geriatric outpatients. Eur Neuropsychopharmacol 1994; 4: 332-3
25. Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 1995; 56: 229-37
26. van Moffaert M, Bartholomé F, Cosyns P, et al. A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression. Hum Psychopharmacol 1995; 10: 393-405
27. Patris M. Citalopram and fluoxetine. Proceedings of the International Symposium on Citalopram: new trends in treatment of depression: 1995 Sep 16; Paris
28. Patris M, Bouchard JM, Bougerol T. et al. Citalopram versus fluoxetine. A double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1946; 11 (2): 129-36
29. Ansseau M, Gabriëls A, Loyens J, et al. Controlled comparison of paroxetine and fluvoxamine in major depression. Hum Psychopharmacol 1994; 9: 329-36
30. Kiev A, Feiger A. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clinical Psychiatry. In press
31. Nemeroff CB, Ninan PT, Ballenger JC, et al. Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients. Depression 1996; 3: 163-9
32. Haffmans PMJ, Timmerman L, Hoogduin CAL, LUCIFER group. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients. Int Clin Psychopharmacol 1996; 11: 157-64
33. Rapaport M, Coccaro E, Sheline E, et al. Comparison of fluvoxamine and fluoxetine in major depression [abstract]. Eur Neuropsychopharmacol 1995; 5 (3): 304
34. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
35. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychology 1967; 6: 278-96
36. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., rev. Washington, DC: American Psychiatric Association, 1987
37. de Wilde J, Spiers R, Mertens C, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Hosp Formul 1993; 28: 36-40
38. Schöne W. A double-blind comparison of paroxetine and fluoxetine in the treatment of geriatric patients with major depression [abstract]. Eur Neuropsychopharmacol 1992; 2: 301
39. Schöne W. Paroxetine in the treatment of geriatric depressed patients - a double-blind comparison with fluoxetine. Fortschr Neurol Psychiatr 1994; 62: 18-22
40. Geretsegger C, Bohmer F, Ludwig M. Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol 1994; 9: 25-9
41. Ansseau M, Gabriels A, Loyens J, et al. A double-blind comparison of paroxetine and fluvoxamine in major depression. J Eur Coll Neuropsychopharmacol 1993; 3: 323-4
42. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9
43. Beck AT, Beamesderfer A. Assessment of depression, the depression inventory. In: Pichot P, Olivier-Martin R, editors. Psychological measurements in psychopharmacology and modern pharmacopsychiatry 7. Basel: Karger, 1974: 151-69
44. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-5
45. Arrindell WA, Ettema JHM. Handleiding bij een multi-dimensionele psychopathologie-indicator. Lisse: Swets & Zeitlinger, 1986
46. US Department of Health and Human Sciences. Depression in primary care, vol. 2. Treatment of major depression (clinical practice guideline number 5). AHCPR Publication No. 93-0551. Rockville (MD): U.S. Department of Health and Human Sciences, 1993
47. Brown WA , Harrison W. Are patients who are intolerant to one SSR1 intolerant to another? Psychopharmacol Bull 1992; 28: 253-6